By now we should all have heard of the incredible weight loss results from GLP-1 receptor agonist medications and their ever-growing popularity. All over the UK, people are searching for access to ‘game changing’ medications to solve their weight problems.
Searches for semaglutide, tirzepatide and liraglutide (brand names WeGovy/Ozempic, Mounjaro, and Saxenda respectively) have increased dramatically in the past year, and interest continues to rise.
That’s because for the first time ever, there seems to be a potential long-term solution to the obesity epidemic that has afflicted the world over the past 30 years.
If you’re on a weight loss journey and are prescribed medication to aid in this process, it’s essential to manage your medication intake effectively during Ramadan to ensure both your health and adherence to religious obligations.
Menopausal women are the fastest growing demographic in the UK workforce with a third of the UK’s female population, around 13 million women, currently in the perimenopause or menopause stage of life. Menopausal age women between 45 and 54 make up 11% of the UK working demographic and 23% of all women in employment.
Menopause, whilst a natural life transition that half the population will go through, has traditionally been a taboo subject particularly between men and women. A UCL-led study carried out in May 2021 found that 9 out 10 women were never educated about the menopause – it’s therefore no stretch to conclude that men have generally been even less informed on what to expect and how to deal with it, especially in the workplace.
Despite the enormous popularity of WeGovy and its incredible impact on weight loss, a shortage of the injectable weight loss therapy has been ongoing in recent months.
The semaglutide-containing injection has been dubbed “game-changing” for the treatment of obesity, and demand has been high, but manufacturer Novo Nordisk has struggled to keep up and has only released limited stock.
Obesity has been an increasingly concerning potential for change in the world. Impacting millions of people already, there is no surprise that its effect on society is far reaching. Global health, individual wellbeing, the economy, and the workplace: obesity’s wrath knows no bounds.
Mounjaro, also known as tirzepatide, is an innovative prescription medication that has shown great potential in promoting weight loss in clinical trials. Due to rising levels of obesity, and therefore increasing need for treatments, many people are rushing to try game-changing medications like Mounjaro to solve their problems.
In recent years, GLP-1 receptor agonists, also known as GLP-1s, have gained significant attention for their potential in promoting weight loss. These medications, including Ozempic and Saxenda, were originally developed for the treatment of type 2 diabetes but have also shown promising results in helping individuals achieve their weight loss goals.
Mounjaro, also known as tirzepatide, is an innovative prescription medication that has recently gained attention for its effectiveness in promoting weight loss. Originally developed by pharmaceutical company Eli Lilly as a treatment for individuals with type 2 diabetes, Mounjaro has shown remarkable impact on weight management, potentially revolutionizing obesity treatment.
With all the talk about the effect of “skinny jabs” and their game changing weight loss results, people around the UK who have struggled with their weight are curious to see how they can get their hands on it. However, it’s important to remember that WeGovy is a medication in the form of an injection, and safety surrounding new medications should always be the upmost importance.
Are you struggling to lose weight and looking for effective solutions? Mounjaro, a weight loss medication containing tirzepatide, may be the answer you’ve been searching for. In this blog post, we will explore how Tirzepatide, the active ingredient in Mounjaro, helps with weight loss and why it is gaining attention in the medical community.
